Navigation Links
Study shows SBRT for stage I NSCLC safe and effective
Date:7/1/2013

DENVER Stereotactic body radiotherapy (SBRT) is considered the treatment of choice for early-stage nonsmall-cell lung cancer (NSCLC) if patients are inoperable because of additional medical conditions. This is based on several prospective phase II trials, which reported consistently high rates of local tumor control. However, these studies only included small number of patients, the methodology of SBRT varied between the studies and SBRT was mainly practiced in specialized centers. Therefore, safety and efficacy of SBRT practiced in routine clinical practice outside of study protocols is not well analyzed.

A working group called Extracranial Stereotactic Radiotherapy was formed within the German Society for Radiation Oncology and this group performed a patterns-of-care and patterns-of-outcome analysis looking at safety and efficacy of SBRT for stage I NSCLC in Germany and Austria. Their research, published in the August issue of the Journal of Thoracic Oncology (JTO), concludes SBRT for stage I NSCLC was safe and effective in this multi-institutional environment. In addition, radiotherapy dosage was identified as a major treatment factor influencing local tumor control and overall survival.

The researchers looked at data from 582 patients treated at 13 institutions between 1998 and 2011. Average follow-up for all patients was 21.4 months and the maximum was 144 months (12 years); follow-up was more than 3 years for 108 patients. Three-year freedom from local progression was 79.6 percent for all 582 patients.

The biological effective dosage was the most significant factor influencing freedom from local progression and overall survival. No evidence of a learning curve or improvement of results with larger SBRT experience and implementation of new radiotherapy technologies was observed. The group concluded that SBRT for stage I NSCLC was safe and effective in this multi-institutional, academic environment, despite considerable inter-institutional variability and time trends in SBRT practice.


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Study links cardiac hormone-related inflammatory pathway with tumor growth
2. How to boost Hispanics participation in clinical trials? Relate to them, Moffitt study shows
3. Impact of iPad® on radiology residents daily clinical duties is limited, study suggests
4. New study on popular prostate cancer protein provides insight into disease progression
5. Study finds dramatic increase in hospitalization of US children with inflammatory bowel disease
6. GAP-AF study helps to define optimal approach to ablation
7. New Study: Alcohol Drinkers May Face Long Term Health Issues
8. A Study Shows That Mom’s Obesity Surgery May Help Break Cycle in Obese Kids
9. New Study Casts Doubt on FDA Pradaxa Conclusions
10. Results of landmark 11-year study on weight losss effect on heart disease risks published today
11. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... ... facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of ... opportunity for area-residents to celebrate two great years while also familiarizing themselves with ...
(Date:3/27/2017)... HOUSTON, Texas (PRWEB) , ... March 27, 2017 , ... ... and hard of hearing, is bringing its latest products to the Deaf Seniors of ... attendees will have the opportunity to meet with knowledgeable ASL friendly staff from Harris ...
(Date:3/25/2017)... ... 2017 , ... Norland at Swissray is pleased to announce the release of the ... ELITE DXA has an active scan window, which is more than double that of existing ... scan area could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
(Date:3/24/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) has named ... in their 12th year, are among the most prestigious in radiology marketing because a ... were retooled to recognize achievements in both large budget (over $5,000) and small budget ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 ... and technology platform for value-based precision medicine, ... multi-year collaboration with Novartis Pharmaceuticals Corporation to ... breast cancer patients. As part ... the previous announced collaboration entered into January ...
(Date:3/27/2017)... 2017 Arena Pharmaceuticals, Inc. (NASDAQ: ... small molecule drugs across multiple therapeutic areas, today announced that ... will present a corporate update at the 16th Annual Needham ... conference will take place April 4-5, 2017 at the Westin ... , NY.  A live audio webcast of ...
Breaking Medicine Technology: